Sign Up
Stories
MetrioPharm's MP1032 Shows Promising Results in COVID-19 Treatment
Share
Advancements in Antibodies to Protect Im...
Advancements in Cancer Treatment and Mar...
Advancements in Medical Trials
AI-Powered Antigen Research Partnership
BioNTech's mRNA Cancer Vaccine Progress
Breakthrough Animal Study for EVX-B1 Vac...
Overview
API
MetrioPharm AG publishes trial data for its lead compound MP1032, showing its potential in reducing mortality and early recovery in COVID-19 patients. The compound also shows promise as a treatment for Long Covid and other infectious diseases.
Ask a question
How does MP1032 compare to other treatments for COVID-19 and Long Covid?
What are the potential implications of MP1032's success in combating infectious diseases?
What are the specific mechanisms of action of MP1032 in reducing mortality and improving recovery?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage